#AI reads Urine# Urinary exosomal RAB11A serves as a novel non-invasive biomarker for diagnosis, treatment response monitoring, and prognosis in small cell lung cancer
Published 10 September, 2025
The study focuses on small cell lung cancer (SCLC), an aggressive disease with a poor prognosis for which existing diagnostic and monitoring methods have limitations. By analyzing urine samples from 90 SCLC patients (divided into untreated, partial/complete remission, and relapsed groups) and 10 healthy controls, urinary exosomes were isolated via ultracentrifugation. Combined with data-independent acquisition mass spectrometry (DIA-MS), parallel reaction monitoring (PRM), and immunohistochemistry techniques, the study found that the RAB11A protein in urinary exosomes was significantly overexpressed in SCLC patients. The area under the curve (AUC) for distinguishing SCLC patients from healthy controls was 0.91 (with a sensitivity of 85% and a specificity of 92%), and it also showed good potential in monitoring treatment response (AUC = 0.86) and early warning of disease relapse (AUC = 0.90). Additionally, the positive expression rate of RAB11A in SCLC tissues (70%) was significantly higher than that in adjacent normal tissues (33%). Ultimately, the study confirmed that urinary exosomal RAB11A is expected to serve as a novel non-invasive biomarker for SCLC diagnosis, treatment response monitoring, and early detection of relapse, providing new insights for improving the clinical management of SCLC.
Clin Proteomics. 2025 Aug 25;22(1):30. doi: 10.1186/s12014-025-09554-4.
Youhe Gao
Statement: During the preparation of this work the author(s) used Doubao / AI reading for summarizing the content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.
For earlier AI Reads Urine articles：